Trial Profile

A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dinutuximab (Primary) ; Iobenguane (Primary) ; Sargramostim (Primary) ; Vorinostat (Primary)
Indications Neuroblastoma
Focus Adverse reactions

Most Recent Events

16 Apr 2025 Number of treatment arms has been changed from 2 to 4. Primary endpoints has been amended.
16 Apr 2025 Status changed from active, no longer recruiting to completed.
04 Sep 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com